AIRLINK 72.59 Increased By ▲ 3.39 (4.9%)
BOP 4.99 Increased By ▲ 0.09 (1.84%)
CNERGY 4.29 Increased By ▲ 0.03 (0.7%)
DFML 31.71 Increased By ▲ 0.46 (1.47%)
DGKC 80.90 Increased By ▲ 3.65 (4.72%)
FCCL 21.42 Increased By ▲ 1.42 (7.1%)
FFBL 35.19 Increased By ▲ 0.19 (0.54%)
FFL 9.33 Increased By ▲ 0.21 (2.3%)
GGL 9.82 Increased By ▲ 0.02 (0.2%)
HBL 112.40 Decreased By ▼ -0.36 (-0.32%)
HUBC 136.50 Increased By ▲ 3.46 (2.6%)
HUMNL 7.14 Increased By ▲ 0.19 (2.73%)
KEL 4.35 Increased By ▲ 0.12 (2.84%)
KOSM 4.35 Increased By ▲ 0.10 (2.35%)
MLCF 37.67 Increased By ▲ 1.07 (2.92%)
OGDC 137.75 Increased By ▲ 4.88 (3.67%)
PAEL 23.41 Increased By ▲ 0.77 (3.4%)
PIAA 24.55 Increased By ▲ 0.35 (1.45%)
PIBTL 6.63 Increased By ▲ 0.17 (2.63%)
PPL 125.05 Increased By ▲ 8.75 (7.52%)
PRL 26.99 Increased By ▲ 1.09 (4.21%)
PTC 13.32 Increased By ▲ 0.24 (1.83%)
SEARL 52.70 Increased By ▲ 0.70 (1.35%)
SNGP 70.80 Increased By ▲ 3.20 (4.73%)
SSGC 10.54 No Change ▼ 0.00 (0%)
TELE 8.33 Increased By ▲ 0.05 (0.6%)
TPLP 10.95 Increased By ▲ 0.15 (1.39%)
TRG 60.60 Increased By ▲ 1.31 (2.21%)
UNITY 25.10 Decreased By ▼ -0.03 (-0.12%)
WTL 1.28 Increased By ▲ 0.01 (0.79%)
BR100 7,566 Increased By 157.7 (2.13%)
BR30 24,786 Increased By 749.4 (3.12%)
KSE100 71,902 Increased By 1235.2 (1.75%)
KSE30 23,595 Increased By 371 (1.6%)
World

South Korea suspends AstraZeneca shots for people under 60 amid European review

  • The European Medical Agency (EMA) is due to announce the results of a review on whether some cases of blood clotting in adults may be linked to the AstraZeneca shot.
  • South Korea's food and drug safety ministry said on Wednesday it had granted final approval for Johnson & Johnson's (J&J) vaccine after a panel of experts ruled the single-dose shot was safe and effective.
Published April 7, 2021

SEOUL: South Korea said on Wednesday it will temporarily suspend providing AstraZeneca's COVID-19 vaccine to people below 60 amid a European review, while approving a Johnson & Johnson shot in a bid to speed up its inoculation rollout.

The European Medical Agency (EMA) is due to announce the results of a review on whether some cases of blood clotting in adults may be linked to the AstraZeneca shot.

The announcement is due at 1400 GMT.

Global controversy over the efficacy and side-effects of some COVID-19 vaccines has caused some delays in South Korea's vaccination campaign, which kicked off in late February with the goal of reaching herd immunity in November.

AstraZeneca has said previously its studies have found no higher risk of clots because of its vaccine, millions of doses of which have been administered worldwide. The World Health Organization and EMA have both said the benefits outweigh the risks.

South Korea's food and drug safety ministry said on Wednesday it had granted final approval for Johnson & Johnson's (J&J) vaccine after a panel of experts ruled the single-dose shot was safe and effective.

J&J is the third COVID-19 vaccine maker to be authorised in South Korea, after AstraZeneca and Pfizer /BioNTech, both of which require two doses.

Authorities are seeking to speed up a national vaccination campaign despite global supply shortages while expanding preemptive testing and tracing efforts amid concerns over a potential fourth wave of infections.

The Korea Disease Control and Prevention Agency (KDCA) reported 668 new cases for Tuesday, the highest level since Jan. 8, with clusters developing in kindergartens, saunas, bars and churches, mostly in the greater Seoul area.

To date, total infections stand at 106,898, with 1,756 deaths.

"If the fourth wave of infections becomes a reality, a disruption to vaccination would be inevitable, as well as dealing a big blow to our economy," Prime Minister Chung Sye-kyun told a government meeting.

Health officials called on the public to refrain from non-essential gatherings and strictly log visits to crowded venues to help with epidemiological work in case of any outbreak.

They also said they would announce new social distancing rules on Friday after discussion with experts and local governments.

The country has so far administered over a million doses of vaccine among medical workers and high-risk groups since the start of its inoculation drive in February, yet authorities face a backlash for relying on the global vaccine-sharing programme COVAX, which has run into delays.

Comments

Comments are closed.